Novo Nordisk Raises Its Outlook: Can Oral Wegovy Sustain the Next Phase of Growth?

A recovery signal, with several tests still ahead

Novo Nordisk’s November 4 results strengthened the case that oral Wegovy is becoming a meaningful commercial contributor. They also raised a more demanding question: can that contribution produce durable growth in cash available to shareholders?

The company raised its 2026 outlook, while reported and adjusted operating profit moved in opposite directions. Product uptake, accounting adjustments and future pricing need to be read separately.

1. Better guidance still centers on a flat year

Novo raised its constant-currency outlook for both adjusted sales growth and adjusted operating profit growth from minus 6% to 0%, to minus 2% to plus 2%. [1]

That is a meaningful improvement. The midpoint moves from a 3% decline to approximately flat, and the downside end improves. The range still allows a modest annual decline, however. Greater confidence in this year’s result does not by itself establish a return to sustained faster growth.

Constant-currency figures seek to separate exchange-rate translation from the underlying comparison. Adjusted figures exclude specified items under the company’s definitions. Investors need consistent measures before drawing conclusions about growth or margins.

2. Assess the whole franchise

Third-quarter oral Wegovy sales were DKK 5.394 billion. Injectable Wegovy generated DKK 20.407 billion, down 2% at constant exchange rates. Total obesity sales rose 22% on that basis. [1]

Oral Wegovy therefore represented approximately 21% of combined oral and injectable Wegovy sales, calculated from those amounts. This is a franchise sales proportion, not a share of total company revenue.

New formulation sales can come from previously untreated patients, people switching from competitors, or patients moving from the company’s own injectable product. Those routes have different implications for incremental revenue.

Adding every oral sale to an unchanged injectable forecast risks double-counting. Conversely, a decline in injectable revenue does not prove cannibalization: price, geographic mix, inventory and actual use can all affect sales. Patient-source and persistence data are needed to distinguish these mechanisms.

3. Check the denominator behind market share

Novo’s investor presentation puts oral Wegovy at roughly 80% of U.S. new-to-brand prescriptions for oral obesity medicines. It also reports that the broader Wegovy franchise accounts for more than half of new patient starts in branded U.S. obesity medicines. [2]

These measures answer different questions. One focuses on oral medicines; the other covers a broader branded obesity category. Neither is identical to the share of all treated patients or sales revenue.

New prescriptions illuminate the competitive entry point. Durable revenue also depends on continued treatment, dose progression and net revenue over time. Prescription counts are not unique-patient counts, since one patient may refill repeatedly.

The next commercial test is therefore who enters treatment, who stays and how long they continue. Early launch interest needs to translate into sustained use.

4. Why adjusted profit rose while reported profit fell

Third-quarter adjusted operating profit rose 27% at constant currency, while reported operating profit declined 9%. The quarter included approximately DKK 8.7 billion of noncash impairments related to ziltivekimab and manufacturing-network adjustments. Approximately DKK 9 billion of transformation costs in the prior-year quarter also lowered the comparison base. Some one-time expenses remained within this quarter’s adjusted result. [1]

A lower expense burden can improve the business, but the full profit increase cannot be attributed to stronger product demand or extrapolated as a recurring growth rate.

“Adjusted” also does not mean that every unusual expense has disappeared. Investors should examine the reconciliation and the costs still included.

Noncash impairment generally does not mean an equivalent new cash payment occurred this quarter. It can nevertheless reveal that an earlier investment no longer supports its previous carrying value. Separate that charge when examining recurring operations, while retaining it when assessing capital-allocation decisions. A past cash outlay still has economic consequences.

5. Revenue, earnings and cash answer different questions

Nine-month reported sales included a roughly DKK 26.8 billion reversal of a U.S. 340B sales-rebate provision recognized in the first quarter. Novo states that the reversal itself had no cash impact. Adjusted nine-month sales grew 2% at constant currency. [1]

In simplified accounting terms, an earlier estimate of a rebate obligation is reduced and part of the provision is reversed. The resulting accounting improvement does not mean an equal amount of additional medicines was sold or fresh cash collected. This explanation illustrates the accounting relationship; it does not establish the legal basis for the 340B adjustment.

Timing matters too: a first-quarter reversal should not be used to explain all third-quarter revenue movements.

Novo also raised its full-year free-cash-flow outlook and lowered expected capital expenditure. [2] Cash improvement is useful, but its source matters. Better operations, payment timing, inventory and other working-capital movements, or lower construction spending can have different implications for persistence.

Less capital spending preserves cash today. Whether it helps long-term value depends partly on whether future supply remains adequate for demand.

6. The 2027 price question

Novo previously announced that selected U.S. Wegovy, Ozempic and Rybelsus list prices would fall to $675 per month from January 1, 2027. The announcement says those changes do not affect direct-to-patient self-pay prices. This was an earlier announcement with a future effective date, rather than a new price cut announced in today’s results. [3]

List price, patient out-of-pocket cost and the manufacturer’s realized net price are different measures. Rebates, discounts and channel arrangements mean a list-price reduction cannot be translated one-for-one into a reduction in manufacturer net revenue per patient.

The arithmetic linking price and volume still matters. In a hypothetical example, if net revenue per unit falls from 100 to 80, unit volume must grow 25% to preserve revenue: 80 multiplied by 1.25 equals 100. With only 20% volume growth, revenue remains 4% lower.

These are teaching assumptions, not a forecast of Novo’s pricing, and they exclude cost changes. They explain why more people receiving treatment does not automatically produce proportionately greater shareholder returns.

An oral formulation can expand treatment access. Commercial value depends on whether incremental use compensates for changes in net revenue per unit, and on the spending needed to acquire and retain patients.

7. What would make the recovery more durable?

Four checkpoints matter:

• Franchise incrementality: sustained net-sales and treatment growth across oral and injectable products together.
• Patient persistence: repeat use after initiation, rather than short-lived trials.
• Profit quality: improvement after favorable prior-year expense comparisons fade.
• Cash conversion: recurring cash after net-pricing changes, channel effects, capital expenditure and research investment.

Today’s results support a narrower but meaningful conclusion: oral Wegovy is making an observable commercial contribution and the annual outlook has improved. A longer-term investment case still needs to combine the new product’s increment, changes in established products and pricing pressure.

Even favorable answers to those operating questions need to be compared with expectations already embedded in the share price. A guidance increase alone cannot establish value per share.

Novo is demonstrating a new source of growth. It must now show how that growth can produce more durable shareholder cash returns after competition and investment.

Primary sources

[1] Novo Nordisk, financial report for the first nine months of 2026, November 4, 2026: Company announcement.

[2] Novo Nordisk, Q3 2026 investor presentation: Presentation.

[3] Novo Nordisk U.S., February 24, 2026 list-price announcement: Official release.

Information as of November 4, 2026. Growth rates are at constant currency unless otherwise stated. Arithmetic examples are hypothetical; no target price or investment rating is assigned. The website’s automatically generated BioScore is not independently verified for this note.